Download as PDF

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of genes, today announced that the Company and its collaborators from the Dana-Farber Cancer Institute will present new preclinical data on SY-1365, a first-in-class selective cyclin-dependent kinase 7 (CDK7) inhibitor currently in a Phase 1 trial in patients with advanced solid tumors, at the American Association for Cancer Research (AACR) Annual Meeting taking place April 14-18, 2018 in Chicago.

The data, which will be presented in both a poster discussion session and a poster session, show that SY-1365 has significant anti-tumor activity in multiple models of treatment-resistant ovarian cancer. The data also identify potential biomarkers of response to SY-1365. Syros plans to open expansion cohorts in mid-2018 in its ongoing Phase 1 trial to evaluate SY-1365 in patients with ovarian cancer, as well as to evaluate these potential biomarkers (ClinicalTrials.gov identifier: NCT03134638).

Details on the presentations are as follows:

Presentation Title: SY-1365, a selective CDK7 inhibitor, exhibits potent anti-tumor activity against ovarian cancer models in vitro and in vivo
Session Category: Molecular and Cellular Biology/Genetics
Presenter: Panagiotis A. Konstantinopoulos, M.D., Ph.D., Dana-Farber Cancer Institute
Abstract Number: 1343

Poster Discussion Session
Date & Time: Sunday, April 15, 4:00 p.m. - 5:00 p.m. CDT
Session Title: Targeting the Cell Cycle: Mechanism and Therapy – Poster Discussion
Location: McCormick Place South, Level 4, Room S402

Poster Session
Date and Time: Monday, April 16, 8:00 a.m. - 12:00 p.m. CDT
Session Title: Targeting the Cell Cycle: Mechanism and Therapy
Poster Session Location: McCormick Place South, Exhibit Hall A, Poster Section 23

About Syros Pharmaceuticals
Syros is pioneering the understanding of the non-coding region of the genome to advance a new wave of medicines that control expression of genes. Syros has built a proprietary platform that is designed to systematically and efficiently analyze this unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations. Because gene expression is fundamental to the function of all cells, Syros’ gene control platform has broad potential to create medicines that achieve profound and durable benefit across a range of diseases. Syros is currently focused on cancer and monogenic diseases and is advancing a growing pipeline of gene control medicines. Syros’ lead drug candidates are SY-1425, a selective RARα agonist in a Phase 2 clinical trial for genomically defined subsets of patients with acute myeloid leukemia and myelodysplastic syndrome, and SY-1365, a selective CDK7 inhibitor in a Phase 1 clinical trial for patients with advanced solid tumors. Led by a team with deep experience in drug discovery, development and commercialization, Syros is located in Cambridge, Mass.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including without limitation statements regarding the Company’s ability initiate expansion cohorts in the Phase 1 clinical trial of SY-1365 in ovarian and breast cancer in mid-2018, whether potential biomarkers of response to SY-1365 will result in a successful patient selection strategy, and the benefits of Syros’ gene control platform. The words ‘‘anticipate,’’ ‘‘believe,’’ ‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ ‘‘intend,’’ ‘‘may,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘target,’’ ‘‘should,’’ ‘‘would,’’ and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including Syros’ ability to: advance the development of its programs, including SY-1365, under the timelines it projects in current and future clinical trials; demonstrate in any current and future clinical trials the requisite safety, efficacy and combinability of its drug candidates; replicate scientific and non-clinical data in clinical trials; successfully develop a companion diagnostic test to identify patients with predictive biomarkers; obtain and maintain patent protection for its drug candidates and the freedom to operate under third party intellectual property; obtain and maintain necessary regulatory approvals; identify, enter into and maintain collaboration agreements with third parties, including its ability to perform under the collaboration agreement with Incyte; manage competition; manage expenses; raise the substantial additional capital needed to achieve its business objectives; attract and retain qualified personnel; and successfully execute on its business strategies; risks described under the caption “Risk Factors” in Syros’ Annual Report on Form 10-K for the year ended December 31, 2017, which is on file with the Securities and Exchange Commission; and risks described in other filings that Syros makes with the Securities and Exchange Commission in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and Syros expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise.

Media Contact:
Syros Pharmaceuticals
Naomi Aoki, 617-283-4298
naoki@syros.com
or
Investor Contact:
Stern Investor Relations, Inc.
Hannah Deresiewicz, 212-362-1200
hannahd@sternir.com

Source: Syros Pharmaceuticals

Released March 14, 2018